About NexusPharma
NexusPharma is a Healthcare company based in Philadelphia (United States) founded in 2005 by Vladimir Khazak, and was acquired by Genesis Biotechnology Group in June 2019. Cancer therapeutic agents are developed via xenograft model testing. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
NexusPharma was founded in 2005 and is based in Philadelphia, United States. Operations focus on the biotechnology sector, where patient-derived xenograft models and cell lines are created for evaluating approved therapeutic agents and drugs. These resources support precision medicine applications through rigorous testing protocols. The companys work emphasizes oncology research and development in a clinical context.
- Headquarters Philadelphia, United States
- Founders Vladimir Khazak
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website nexuspharm.com
- Social LinkedIn Facebook
- Acquired by Genesis Biotechnology Group (Jun 2019)
- Investors
- Acquired byGenesis Biotechnology Group
(Jun 2019)
Investors in NexusPharma
NexusPharma has secured backing from 1 investor. Prominent investors backing the company include Genesis Drug Discovery & Development.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A contract research organization focused on drug discovery and development. | gd3services.com | Hamilton, United States |
Investor details for NexusPharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NexusPharma
2 people are tracked at NexusPharma (2 in leadership).
| Name | Role | Group |
|---|---|---|
Vladimir Khazak | Co-Founder | Leadership |
Usman Ahmed | President and Chief Executive Officer | Leadership |
Complete people profiles for NexusPharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NexusPharma
2 dated milestones of NexusPharma across 14 years, from founding to its latest funding, stage changes and deals.
- Founded NexusPharma is founded.
- Exit Acquired by Genesis Biotechnology Group.
Competitors of NexusPharma
NexusPharma has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of NexusPharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as NexusPharma (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nexuspharma
Complete news archive for NexusPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NexusPharma
NexusPharma was founded in 2005.
NexusPharma is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
NexusPharma was founded in 2005 and is based in Philadelphia, United States. Operations focus on the biotechnology sector, where patient-derived xenograft models and cell lines are created for evaluating approved therapeutic agents and drugs. These resources support precision medicine applications through rigorous testing protocols. The companys work emphasizes oncology research and development in a clinical context.
NexusPharma's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
NexusPharma has 1 investor. Key investors include Genesis Drug Discovery & Development.
Yes. NexusPharma was acquired by Genesis Biotechnology Group in June 2019.